

Cumulative Candida Antibigram Nebraska Medical Center Jan 1 2021 - Dec 31, 2023 Admitted patients only, first isolate per patient	Isolates	Amphotericin B*	Fluconazole	Itraconazole*	Miconazole†	Posaconazole*	Voriconazole
<i>Candida albicans</i>	109	100	92	53**	99	91	92
<i>Candida glabrata (Nakasemyces glabrata)</i>	83	100	92†/80**	94^	93	61^	45*^
<i>Candida tropicalis</i>	15	100	73‡/60	80/46**	93	53/20**	60
<i>Candida albicans/dubliniensis</i>	14	100/ 85**	100	92/29**	100	100	100
<i>Candida krusei (Pichia kudriavzevii)</i>	8	100	IR	100^	100	100^	100
<i>Candida lusitanae (Clavispora lusitanae)</i>	6	R	66*	100	100*	50	-
<i>Candida parapsilosis</i>	3	100	67	100/67**	33	100/50**	100
<i>Candida auris</i>	1	MIC=2	MIC >256	MIC=0.5	100* (MIC=0.12)	MIC=0.25	MIC=4

*ECVs used to recognize resistance (CLSI M57S 2022, value above ECV considered R)

**EUCAST Breakpoints applied: generally lower than CLSI

<https://www.eucast.org/astoffungi/clinicalbreakpointsforantifungals>

^insufficient data to correlate in vitro susceptibility testing/ECV and clinical outcomes

‡For *C. albicans*, all MIC values at NMC are >3X below breakpoint, ~90% w/ MIC ≤0.015 (16X below breakpoint)

†For *C. glabrata*, a fluconazole MIC ≤ 32 is considered susceptible dose-dependent (SDD) and clinicians should determine whether fluconazole is appropriate in the specific clinical context. If so, patients should receive the maximum dosage regimen of fluconazole. Dosing of 400-800mg daily can generally treat MICs of 4-8 mg/L. Expert consultation on dose selection is recommended.

‡For *C. tropicalis*, fluconazole reported as susceptible-dose dependent (SDD)/Susceptible

CLSI ECVs and Breakpoints (M57S 2022 & M2744 2022)

Species	Drug	ECV	Clinical Breakpoints				Notes
			S </=	I	SDD	R >/=	
<i>Candida albicans</i>	Amphotericin	2	-	-	-	-	
	Fluconazole	0.5	2		4	8	
	Itraconazole	none	-	-	-	-	
	Micafungin	0.03	0.25	0.5	-	1	
	Posaconazole	0.06	-	-	-	-	
	Voriconazole	0.03	0.12	0.25-0.5	-	1	
<i>Candida glabrata</i> (<i>Nakasemyces glabrata</i>)	Amphotericin	2	-	-	-	-	
	Fluconazole	8	-	-	32	64	No S category
	Itraconazole	4	-	-	-	-	
	Micafungin	0.03	0.06	0.12	-	0.25	
	Posaconazole	1	-	-	-	-	
	Voriconazole	-	-	-	-	-	Lack of data for clinical outcomes related to MIC for vori and <i>C. glabrata</i>
<i>Candida tropicalis</i>	Amphotericin	2	-	-	-	-	
	Fluconazole	1	2	-	4	8	
	Itraconazole	0.5	-	-	-	-	
	Micafungin	0.06	0.25	0.5	-	1	
	Posaconazole	0.12	-	-	-	-	
	Voriconazole	0.12	0.12	0.25-0.5	-	1	

Candida albicans/ dubliniensis	Amphotericin	0.5	-	-		-		ECVs listed are specific to <i>C. dublinensis</i> while breakpoints for interpretation belong to <i>C. albicans</i>
	Fluconazole	0.5	2	-	4	8		
	Itraconazole	0.25	-	-	-	-		
	Micafungin	0.12	0.25	0.5	-	1		
	Posaconazole	0.12	-	-	-	-		
	Voriconazole	none	0.12	0.25-0.5	-	1		
Candida krusei	Amphotericin	2	-	-	-	-		
(<i>Pichia kudriavzevii</i>)	Fluconazole	IR	-	-	-	-		
	Itraconazole	1	-	-	-	-		
	Micafungin	0.25	0.25	0.5	-	1		
	Posaconazole	0.5	-	-	-	-		
	Voriconazole	0.5	0.5	1	-	2		
Candida lusitanae	Amphotericin	2	-	-	-	-		
(<i>Clavispora lusitanae</i>)	Fluconazole	1	-	-	-	-		
	Itraconazole	1	-	-	-	-		
	Micafungin	0.5	-	-	-	-		
	Posaconazole	0.06	-	-	-	-		
	Voriconazole	none	-	-	-	-		
Candida parapsilosis	Amphotericin	1	-	-	-	-		
	Fluconazole	2	2		4	8		
	Itraconazole	0.5	-	-	-	-		
	Micafungin	2	2	4	-	8		
	Posaconazole	0.25	-	-	-	-		
	Voriconazole	none	0.12	0.25-0.5	-	1		